Compared with traditional anti‐CTLA4 therapy, recently developed tumour‐conditional anti‐CTLA4 therapy depleted tumour‐infiltrated Tregs, while preserving tissue‐resident Tregs, which preserved antitumour effects and reduced multiorgan immune toxicity.53 This evidence concerns the gene CTLA4 and neoplasm.